EMEA Begins Review of Sibutramine, Recommends Market Withdrawal of Cerivastatin

LONDON (Reuters Health) Mar 21 – The European Medicines Evaluation Agency (EMEA) confirmed on Thursday that its scientific committee had initiated a Community-level review on the risk-benefit of Abbott's anti-obesity drug sibutramine (Reductil/Meridia), which was withdrawn from the market in Italy earlier this month after reports that two patients had died.
A spokesman declined to say who was leading the review, which was requested by Italy. Abbott has said that it is aware of 34 deaths globally but insists there is no evidence that these were caused by the drug, which has been used by millions of patients since it was launched in 1997.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים